Cytosin-Arabinosid

Non-Small Cell Lung Cancer

PfizerPhase 3Active

B

58/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 59/ 100

Competitive context

175 Active assets in the Non-Small Cell Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Anamorelin Helsinn Healthcare SA	Phase 3	BB
Docetaxel Genfleet Therapeutics (Shanghai) Inc.	Phase 4	BB
Atezolizumab National Cancer Institute (NCI)	Phase 4	BB
ETOPOSIDE Pfizer	Phase 3	BB
Irinotecan Intergroupe Francophone de Cancerologie Thoracique	Phase 3	BB

View all 50 →

Same molecule, other indications

Cytosin-Arabinosid is also rated in:

acute promyelocytic leukemiaDormant

A

Indicative ·

82 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

79 / 100

B-cell childhood acute lymphoblastic leukemiaDormant

BBB

Indicative ·

78 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.